J A Maroun

Summary

Affiliation: University of Ottawa
Country: Canada

Publications

  1. pmc Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea
    J A Maroun
    Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario
    Curr Oncol 14:13-20. 2007
  2. pmc Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group
    J Maroun
    Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario
    Curr Oncol 13:67-76. 2006
  3. ncbi request reprint A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer
    J A Maroun
    Medical Oncology, The Ottawa Hospital Regional Cancer Centre, 501 Smyth Road, Ottawa, Ont, Canada K1H 8L6
    Eur J Cancer 42:193-9. 2006
  4. ncbi request reprint Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115
    J A Maroun
    The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
    Ann Oncol 17:1371-8. 2006
  5. pmc Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials
    D J Jonker
    Ottawa Regional Cancer Centre, London, Ontario, Canada
    Br J Cancer 82:1789-94. 2000
  6. doi request reprint Tissue Factor Pathway Inhibitor Gene Polymorphism -33T → C Predicts Improved Disease-Free Survival in Colorectal Cancer
    A K Bazzarelli
    Division of General Surgery, Department of Surgery, University of Ottawa, Ottawa, ON, Canada
    Ann Surg Oncol 23:2274-80. 2016
  7. ncbi request reprint Characterization of a polyclonal antibody to human thymidylate synthase suitable for the study of colorectal cancer specimens
    A S Haqqani
    Department of Biochemistry, Microbiology and Immunology, Ottawa, Ontario, Canada
    J Histochem Cytochem 47:1563-74. 1999
  8. ncbi request reprint Capecitabine in the management of colorectal cancer
    J A Maroun
    Ottawa Regional Cancer Centre, 503 Smyth Rd, Ottawa, ON K1H 1C4, Canada
    Expert Rev Anticancer Ther 1:327-33. 2001
  9. ncbi request reprint Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback
    G P Browman
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    J Clin Oncol 16:1226-31. 1998
  10. pmc Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
    E Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    Br J Cancer 90:1190-7. 2004

Collaborators

Detail Information

Publications10

  1. pmc Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea
    J A Maroun
    Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario
    Curr Oncol 14:13-20. 2007
    ..If a dose reduction is not desired, prophylaxis with intramuscular long-acting release octreotide may be considered.The foregoing recommendations are based on expert opinion and require validation in prospective clinical trials...
  2. pmc Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group
    J Maroun
    Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario
    Curr Oncol 13:67-76. 2006
    ..This article, developed by a group of Canadian experts, provides a framework that will assist clinicians in taking an optimal approach to managing their patients with carcinoid tumour...
  3. ncbi request reprint A National Cancer Institute of Canada Clinical Trials Group Study--IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer
    J A Maroun
    Medical Oncology, The Ottawa Hospital Regional Cancer Centre, 501 Smyth Road, Ottawa, Ont, Canada K1H 8L6
    Eur J Cancer 42:193-9. 2006
    ..3%) experienced partial response. Further evaluation in a randomized study compared to sequential doublets is warranted. Triple combinations could be relevant in curative settings for high-risk patients...
  4. ncbi request reprint Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115
    J A Maroun
    The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada
    Ann Oncol 17:1371-8. 2006
    ..Aplidine is a cyclic depsipeptide isolated from the marine tunicate Aplidium albicans...
  5. pmc Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials
    D J Jonker
    Ottawa Regional Cancer Centre, London, Ontario, Canada
    Br J Cancer 82:1789-94. 2000
    ..Chemotherapy significantly prolongs 1-year survival for patients with metastatic colorectal cancer, and should be offered to those with good performance status...
  6. doi request reprint Tissue Factor Pathway Inhibitor Gene Polymorphism -33T → C Predicts Improved Disease-Free Survival in Colorectal Cancer
    A K Bazzarelli
    Division of General Surgery, Department of Surgery, University of Ottawa, Ottawa, ON, Canada
    Ann Surg Oncol 23:2274-80. 2016
    ..This study was the first to evaluate the impact of this polymorphism on disease-free survival (DFS) in cancer patients after curative resection...
  7. ncbi request reprint Characterization of a polyclonal antibody to human thymidylate synthase suitable for the study of colorectal cancer specimens
    A S Haqqani
    Department of Biochemistry, Microbiology and Immunology, Ottawa, Ontario, Canada
    J Histochem Cytochem 47:1563-74. 1999
    ..Normal colon mucosa showed weak staining, whereas some colorectal cancer specimens stained very strongly with hTS7.4. A clinical study of colorectal cancer using this antibody is in progress. (J Histochem Cytochem 47:1563-1573, 1999)..
  8. ncbi request reprint Capecitabine in the management of colorectal cancer
    J A Maroun
    Ottawa Regional Cancer Centre, 503 Smyth Rd, Ottawa, ON K1H 1C4, Canada
    Expert Rev Anticancer Ther 1:327-33. 2001
    ..The rational development of this targeted drug with its selective activation in tumor tissue is highlighted. The clinical development of capecitabine and its present and future role in the management of colorectal cancer are reviewed...
  9. ncbi request reprint Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback
    G P Browman
    Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    J Clin Oncol 16:1226-31. 1998
    ....
  10. pmc Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
    E Van Cutsem
    University Hospital Gasthuisberg, Leuven, Belgium
    Br J Cancer 90:1190-7. 2004
    ..Capecitabine is a suitable replacement for i.v. 5-FU as the backbone of colorectal cancer therapy...